Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA)

Waleed Sabry, Mohamed Elemary, Thierry Burnouf, Jerard Seghatchian, Hadi Goubran

Research output: Contribution to journalReview article

Abstract

Thrombotic microangiopathies (TMA) are characterized by microangiopathic hemolytic anemia, thrombocytopenia and organ damage resulting from mechanical factors, accumulation of the ultra-large von Willebrand factor multimers or complement-mediated abnormalities. Severe acquired vitamin B12 (Cobalamin - Cbl) deficiency or congenital defective Cbl metabolism could lead to a picture that mimics TMA. The later has been termed metabolism-mediated TMA (MM- TMA). This confusing picture is mediated partly by the large red cell fragmentation coupled with reduced platelet production in the absence of vitamin B12 and partly by the accumulated byproducts and metabolites that induce endothelial injury and hence organ damage. Expensive and complicated treatment for TMA is often initiated on an empiric basis, pending the results of confirmatory tests. In contrast, vitamin B12 Pseudo-TMA and MM-TMA could be treated with proper vitamin B12 supplementation. It is therefore important to identify these disorders promptly. The recent availability of a validated scoring system such as the PLASMIC score uses simple clinical and laboratory parameters. As it incorporates the mean corpuscular volume in its laboratory parameters, this helps in the identification of pseudo and MM-TMA. Perhaps some minor modification of this scoring system by changing the parameters of hemolysis to include reticulocytosis and rather than and/or other hemolytic parameters could even help refine this identification.

Original languageEnglish
Article number102717
JournalTransfusion and Apheresis Science
DOIs
Publication statusAccepted/In press - Jan 1 2020

Fingerprint

Thrombotic Microangiopathies
Vitamin B 12 Deficiency
Vitamin B 12
Reticulocytosis
Erythrocyte Indices
Hemolytic Anemia
von Willebrand Factor
Hemolysis
Thrombocytopenia
Blood Platelets
Wounds and Injuries

Keywords

  • Cobalamin
  • MM-TMA
  • Plasmic score
  • Thrombotic microangiopathy
  • Vitamin B12

ASJC Scopus subject areas

  • Hematology

Cite this

Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA). / Sabry, Waleed; Elemary, Mohamed; Burnouf, Thierry; Seghatchian, Jerard; Goubran, Hadi.

In: Transfusion and Apheresis Science, 01.01.2020.

Research output: Contribution to journalReview article

@article{313914489914417ab38ec578a5ce42bb,
title = "Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA)",
abstract = "Thrombotic microangiopathies (TMA) are characterized by microangiopathic hemolytic anemia, thrombocytopenia and organ damage resulting from mechanical factors, accumulation of the ultra-large von Willebrand factor multimers or complement-mediated abnormalities. Severe acquired vitamin B12 (Cobalamin - Cbl) deficiency or congenital defective Cbl metabolism could lead to a picture that mimics TMA. The later has been termed metabolism-mediated TMA (MM- TMA). This confusing picture is mediated partly by the large red cell fragmentation coupled with reduced platelet production in the absence of vitamin B12 and partly by the accumulated byproducts and metabolites that induce endothelial injury and hence organ damage. Expensive and complicated treatment for TMA is often initiated on an empiric basis, pending the results of confirmatory tests. In contrast, vitamin B12 Pseudo-TMA and MM-TMA could be treated with proper vitamin B12 supplementation. It is therefore important to identify these disorders promptly. The recent availability of a validated scoring system such as the PLASMIC score uses simple clinical and laboratory parameters. As it incorporates the mean corpuscular volume in its laboratory parameters, this helps in the identification of pseudo and MM-TMA. Perhaps some minor modification of this scoring system by changing the parameters of hemolysis to include reticulocytosis and rather than and/or other hemolytic parameters could even help refine this identification.",
keywords = "Cobalamin, MM-TMA, Plasmic score, Thrombotic microangiopathy, Vitamin B12",
author = "Waleed Sabry and Mohamed Elemary and Thierry Burnouf and Jerard Seghatchian and Hadi Goubran",
year = "2020",
month = "1",
day = "1",
doi = "10.1016/j.transci.2019.102717",
language = "English",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA)

AU - Sabry, Waleed

AU - Elemary, Mohamed

AU - Burnouf, Thierry

AU - Seghatchian, Jerard

AU - Goubran, Hadi

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Thrombotic microangiopathies (TMA) are characterized by microangiopathic hemolytic anemia, thrombocytopenia and organ damage resulting from mechanical factors, accumulation of the ultra-large von Willebrand factor multimers or complement-mediated abnormalities. Severe acquired vitamin B12 (Cobalamin - Cbl) deficiency or congenital defective Cbl metabolism could lead to a picture that mimics TMA. The later has been termed metabolism-mediated TMA (MM- TMA). This confusing picture is mediated partly by the large red cell fragmentation coupled with reduced platelet production in the absence of vitamin B12 and partly by the accumulated byproducts and metabolites that induce endothelial injury and hence organ damage. Expensive and complicated treatment for TMA is often initiated on an empiric basis, pending the results of confirmatory tests. In contrast, vitamin B12 Pseudo-TMA and MM-TMA could be treated with proper vitamin B12 supplementation. It is therefore important to identify these disorders promptly. The recent availability of a validated scoring system such as the PLASMIC score uses simple clinical and laboratory parameters. As it incorporates the mean corpuscular volume in its laboratory parameters, this helps in the identification of pseudo and MM-TMA. Perhaps some minor modification of this scoring system by changing the parameters of hemolysis to include reticulocytosis and rather than and/or other hemolytic parameters could even help refine this identification.

AB - Thrombotic microangiopathies (TMA) are characterized by microangiopathic hemolytic anemia, thrombocytopenia and organ damage resulting from mechanical factors, accumulation of the ultra-large von Willebrand factor multimers or complement-mediated abnormalities. Severe acquired vitamin B12 (Cobalamin - Cbl) deficiency or congenital defective Cbl metabolism could lead to a picture that mimics TMA. The later has been termed metabolism-mediated TMA (MM- TMA). This confusing picture is mediated partly by the large red cell fragmentation coupled with reduced platelet production in the absence of vitamin B12 and partly by the accumulated byproducts and metabolites that induce endothelial injury and hence organ damage. Expensive and complicated treatment for TMA is often initiated on an empiric basis, pending the results of confirmatory tests. In contrast, vitamin B12 Pseudo-TMA and MM-TMA could be treated with proper vitamin B12 supplementation. It is therefore important to identify these disorders promptly. The recent availability of a validated scoring system such as the PLASMIC score uses simple clinical and laboratory parameters. As it incorporates the mean corpuscular volume in its laboratory parameters, this helps in the identification of pseudo and MM-TMA. Perhaps some minor modification of this scoring system by changing the parameters of hemolysis to include reticulocytosis and rather than and/or other hemolytic parameters could even help refine this identification.

KW - Cobalamin

KW - MM-TMA

KW - Plasmic score

KW - Thrombotic microangiopathy

KW - Vitamin B12

UR - http://www.scopus.com/inward/record.url?scp=85077302996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077302996&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2019.102717

DO - 10.1016/j.transci.2019.102717

M3 - Review article

AN - SCOPUS:85077302996

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

M1 - 102717

ER -